All In Biotech

Drug Trial Radar · NCT00068770

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy

Last checked: Nov 19, 2026Latest source record: Mar 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

35

Actual

Start

Oct 2003

Primary completion

May 2005

Study completion May 2006

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 11, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.

Conditions

  • Brain and Central Nervous System Tumors

Interventions

  • radiation therapyRadiation

    Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment

  • CelecoxibDrug

    Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of Hepatic Enzyme Inducing Drugs Such as Anticonvulsants, on the PK of CelecoxibTime frame: First dose of celecoxib through completion of radiation, 6 weeks.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Comprehensive Cancer Center at Wake Forest University

    Winston-Salem, North Carolina

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.